Drug Trial Radar · NCT07402915
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jan 26, 2026
Primary completion
Oct 15, 2027
Study completion Oct 15, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal
Interventions
AZD5335Drug
AZD5335 will be administered as IV infusion.
ItraconazoleDrug
Itraconazole capsule will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under curve from time 0 to time 17 days (AUC0-17days)Time frame: Cycle 2 and Cycle 3 (each cycle is of 21 days)
- Maximum plasma drug concentration (Cmax)Time frame: Cycle 2 and Cycle 3 (each cycle is of 21 days)
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Batumi, Georgia · Withdrawn
Research Site
Tbilisi, Georgia · Withdrawn
Research Site
Tbilisi, Georgia · Withdrawn
Research Site
Dublin, Ireland · Recruiting
Research Site
Lisbon, Portugal · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Logroño, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.